NYSE:TEVATeva Pharmaceutical Industries Stock Price, Forecast & News

Teva Pharmaceutical Industries' stock was trading at $9.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TEVA shares have increased by 28.4% and is now trading at $11.57. View which stocks have been most impacted by Coronavirus.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 4 sell ratings, 11 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries will be holding an earnings conference call on Wednesday, August 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) released its quarterly earnings results on Thursday, May, 7th. The company reported $0.76 earnings per share for the quarter, topping analysts' consensus estimates of $0.59 by $0.17. The company had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.15 billion. Teva Pharmaceutical Industries had a positive return on equity of 18.10% and a negative net margin of 4.73%. Teva Pharmaceutical Industries's revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.60 earnings per share. View Teva Pharmaceutical Industries' earnings history.

Teva Pharmaceutical Industries issued an update on its FY20 earnings guidance on Thursday, May, 7th. The company provided earnings per share (EPS) guidance of $2.30-2.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.44. The company issued revenue guidance of $16.6-17.0 billion, compared to the consensus revenue estimate of $16.74 billion.

21 analysts have issued 12-month price targets for Teva Pharmaceutical Industries' stock. Their forecasts range from $8.00 to $16.00. On average, they anticipate Teva Pharmaceutical Industries' stock price to reach $11.50 in the next year. This suggests that the stock has a possible downside of 0.6%. View analysts' price targets for Teva Pharmaceutical Industries.

Press coverage about TEVA stock has been trending very negative on Tuesday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Teva Pharmaceutical Industries earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Teva Pharmaceutical Industries.

Some companies that are related to Teva Pharmaceutical Industries include ASTELLAS PHARMA/ADR (ALPMY), Royalty Pharma (RPRX), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GMAB), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Beigene (BGNE), Sarepta Therapeutics (SRPT), GALAPAGOS NV/S (GLPG) and GRIFOLS S A/S (GRFS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), NVIDIA (NVDA), AT&T (T), Alibaba Group (BABA), Bank of America (BAC), Gilead Sciences (GILD), Micron Technology (MU), Intel (INTC), Cisco Systems (CSCO) and Walt Disney (DIS).

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Teva Pharmaceutical Industries' stock is owned by a number of retail and institutional investors. Top institutional shareholders include IFM Investors Pty Ltd (0.01%), OLD Point Trust & Financial Services N A (0.00%), MERIAN GLOBAL INVESTORS UK Ltd (0.00%), Dfpg Investments LLC (0.00%), Investment House LLC (0.00%) and Envestnet Asset Management Inc. (0.00%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Iris Beck Codner, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Sol J Barer and Sven Dethlefs. View institutional ownership trends for Teva Pharmaceutical Industries.

TEVA stock was sold by a variety of institutional investors in the last quarter, including Dfpg Investments LLC, IFM Investors Pty Ltd, Exane Derivatives, and Investment House LLC. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, and Richard Daniell. View insider buying and selling activity for Teva Pharmaceutical Industries.

TEVA stock was bought by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Envestnet Asset Management Inc., Nelson Van Denburg & Campbell Wealth Management Group LLC, and OLD Point Trust & Financial Services N A. Company insiders that have bought Teva Pharmaceutical Industries stock in the last two years include Sol J Barer, and Sven Dethlefs. View insider buying and selling activity for Teva Pharmaceutical Industries.

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TEVA stock can currently be purchased for approximately $11.57.

Teva Pharmaceutical Industries has a market capitalization of $12.64 billion and generates $16.89 billion in revenue each year. The company earns $-998,000,000.00 in net income (profit) each year or $2.31 on an earnings per share basis. Teva Pharmaceutical Industries employs 40,039 workers across the globe.

The official website for Teva Pharmaceutical Industries is www.tevapharm.com.

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]